🚀 VC round data is live in beta, check it out!
Xeris Biopharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xeris Biopharma and similar public comparables like SSY Group, Compass Therapeutics, Ventyx Biosciences, PYC Therapeutics and more.
Xeris Biopharma Overview
About Xeris Biopharma
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Founded
2005
HQ
Employees
394
Website
Sectors
Financials (LTM)
EV
$1B
Xeris Biopharma Financials
Xeris Biopharma reported last 12-month revenue of $312M and EBITDA of $60M.
In the same LTM period, Xeris Biopharma generated $267M in gross profit, $60M in EBITDA, and $4M in net income.
Revenue (LTM)
Xeris Biopharma P&L
In the most recent fiscal year, Xeris Biopharma reported revenue of $292M and EBITDA of $59M.
Xeris Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $312M | XXX | $292M | XXX | XXX | XXX |
| Gross Profit | $267M | XXX | $249M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | $60M | XXX | $59M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $4M | XXX | $554K | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | — | — | $109M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Xeris Biopharma Stock Performance
Xeris Biopharma has current market cap of $999M, and enterprise value of $1B.
Market Cap Evolution
Xeris Biopharma's stock price is $6.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $999M | 0.0% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXeris Biopharma Valuation Multiples
Xeris Biopharma trades at 3.7x EV/Revenue multiple, and 19.3x EV/EBITDA.
EV / Revenue (LTM)
Xeris Biopharma Financial Valuation Multiples
As of March 21, 2026, Xeris Biopharma has market cap of $999M and EV of $1B.
Equity research analysts estimate Xeris Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xeris Biopharma has a P/E ratio of 236.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $999M | XXX | $999M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 19.3x | XXX | 19.6x | XXX | XXX | XXX |
| EV/EBIT | 42.0x | XXX | 46.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | 4.7x | XXX | XXX | XXX |
| P/E | 236.5x | XXX | 1803.0x | XXX | XXX | XXX |
| EV/FCF | 38.7x | XXX | 41.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xeris Biopharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Xeris Biopharma Margins & Growth Rates
Xeris Biopharma's revenue in the last 12 month grew by 29%.
Xeris Biopharma's revenue per employee in the last FY averaged $0.8M.
Xeris Biopharma's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xeris Biopharma's rule of X is 93% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Xeris Biopharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 93% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 77% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Xeris Biopharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SSY Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Compass Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Ventyx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| PYC Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GH Research | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xeris Biopharma M&A Activity
Xeris Biopharma acquired XXX companies to date.
Last acquisition by Xeris Biopharma was on XXXXXXXX, XXXXX. Xeris Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Xeris Biopharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXeris Biopharma Investment Activity
Xeris Biopharma invested in XXX companies to date.
Xeris Biopharma made its latest investment on XXXXXXXX, XXXXX. Xeris Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Xeris Biopharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xeris Biopharma
| When was Xeris Biopharma founded? | Xeris Biopharma was founded in 2005. |
| Where is Xeris Biopharma headquartered? | Xeris Biopharma is headquartered in United States. |
| How many employees does Xeris Biopharma have? | As of today, Xeris Biopharma has over 394 employees. |
| Who is the CEO of Xeris Biopharma? | Xeris Biopharma's CEO is John P. Shannon. |
| Is Xeris Biopharma publicly listed? | Yes, Xeris Biopharma is a public company listed on Nasdaq. |
| What is the stock symbol of Xeris Biopharma? | Xeris Biopharma trades under XERS ticker. |
| When did Xeris Biopharma go public? | Xeris Biopharma went public in 2018. |
| Who are competitors of Xeris Biopharma? | Xeris Biopharma main competitors are SSY Group, Compass Therapeutics, Ventyx Biosciences, PYC Therapeutics. |
| What is the current market cap of Xeris Biopharma? | Xeris Biopharma's current market cap is $999M. |
| What is the current revenue of Xeris Biopharma? | Xeris Biopharma's last 12 months revenue is $312M. |
| What is the current revenue growth of Xeris Biopharma? | Xeris Biopharma revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of Xeris Biopharma? | Current revenue multiple of Xeris Biopharma is 3.7x. |
| Is Xeris Biopharma profitable? | Yes, Xeris Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xeris Biopharma? | Xeris Biopharma's last 12 months EBITDA is $60M. |
| What is Xeris Biopharma's EBITDA margin? | Xeris Biopharma's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Xeris Biopharma? | Current EBITDA multiple of Xeris Biopharma is 19.3x. |
| What is the current FCF of Xeris Biopharma? | Xeris Biopharma's last 12 months FCF is $30M. |
| What is Xeris Biopharma's FCF margin? | Xeris Biopharma's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Xeris Biopharma? | Current FCF multiple of Xeris Biopharma is 38.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.